Journal of Isfahan Medical School

Journal of Isfahan Medical School

The Effect of Pseudocatalase/Superoxide Dismutase in Treatment of Vitiligo: A Pilot Study

Document Type : Original Article (s)

Authors
Farahnaz Fatemi-Naeini 1
Alireza Vaez-Shooshtari 2
Bahareh Ebrahimi 2
Mohammad Ali Nilforoushzadeh 3
Razieh Molaei 2
1 Associate Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Pseudocatalase/superoxide dismutase (PSD) is a topical gel considered having therapeutic effects in vitiligo. This study was designed to evaluate the efficacy of this combination in vitiligo.Methods: This was a pilot randomized, double‑blind, placebo‑controlled trial on 46 symmetrical vitiligo lesions of limbs in 23 patients referring to dermatology clinics in Isfahan, Iran, in 2010. Patients were received this formula or placebo gels for the right and left lesions. Lesion area and degree of pigmentation were assessed at baseline and 2, 4, and 6 months later.Findings: There were no significant changes in lesion area and perifollicular pigmentation in each group (P =0.05).Conclusion: The results indicated no significant therapeutic effect for pseudocatalase/superoxide dismutase in vitiligo.
Keywords
Pseudocatalase/superoxide dismutase
Efficacy
Vitiligo
  1. Taieb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360(2): 160-9.
  2. Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, Theoharides TC. Neuro-immuno-endocrine processes in vitiligo pathogenesis. Int J Immunopathol Pharmacol 2012; 25(1): 1-7.
  3. Patel NS, Paghdal KV, Cohen GF. Advanced treatment modalities for vitiligo. Dermatol Surg 2012; 38(3): 381-91.
  4. Colucci R, Lotti T, Moretti S. Vitiligo: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2012; 13(13): 1885-99.
  5. Hazneci E, Karabulut AB, Ozturk C, Batcioglu K, Dogan G, Karaca S, et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol 2005; 44(8): 636-40.
  6. Arican O, Kurutas EB. Oxidative stress in the blood of patients with active localized vitiligo. Acta Dermatovenerol Alp Panonica Adriat 2008; 17(1): 12-6.
  7. Gawkrodger DJ. Pseudocatalase and narrowband ultraviolet B for vitiligo: clearing the picture. Br J Dermatol 2009; 161(4): 721-2.
  8. Yuksel EP, Aydin F, Senturk N, Canturk T, Turanli AY. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol 2009; 19(4): 341-4.
  9. Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009; 161(4): 910-7.
  10. Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008; 22(11): 1359-64.
  11. Schallreuter KU, Rokos H. Vitix--a new treatment for vitiligo? Int J Dermatol 2005; 44(11): 969-70.
  12. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 2011; 11: 21.
Journal of Isfahan Medical School
Volume 31, Issue 269 - Serial Number 269
November and December 2014
Pages 2309-2314

  • Receive Date 22 January 2014
  • Accept Date 06 April 2022